In late 2025, the biosimilars market picked up real momentum. New approvals in Europe, strategic product launches, and major partnerships in the U.S. show just how fast this space is growing — as highlighted in a recent article by The Center for Biosimilars.
At Biokinetica, we see this progress as a strong reminder of how important early-phase clinical research is for biosimilar development. Getting safety, pharmacokinetics, and comparability right from the start helps build regulatory confidence and sets the stage for successful market entry.
As the biosimilars landscape continues to grow, strong collaboration and trust in early-phase research matter more than ever. Together, we can help bring high-quality, affordable biologics to patients around the world.
👉 Read the full article here:
center for biosimilars
💡 Looking to move your biosimilar program forward? Let’s connect!
